WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.
The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Contacts
LifeSci Advisors:
Brian Ritchie
(212) 915-2578
britchie@lifesciadvisors.com
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined…
Two-day cannabis trade events will connect brands, dispensaries, and budtenders for networking, product showcases, and…
Orange County, California, June 27, 2025 (GLOBE NEWSWIRE) -- Sage Healthspan, a California-based digital health…
You Cannot Silence the SciencePALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- In less…
BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) -- The two leading academic institutions have joined…
Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
